Table 5.
BH3 profiling
| Patient | Disease | Dose Level | BH3 Dependency | Best Response | |
|---|---|---|---|---|---|
| Baseline | On Study | ||||
| 6 | Pre–B-ALL | 1 | BCL-XL | BCL-XL | CR |
| 3 | Pre–B-ALL | 1 | BCL-XL | BCL-XL | PR |
| 1 | Pre–B-ALL | 1 | BCL-XL | BCL-XL | CRi |
| 10 | Pre–B-ALL | 1 | BCL-XL (PB), BCL-2 (BM)a | — | CRp |
| 36 | Pre–B-ALL | 3 | BCL-2 | BCL-2, BCL-XL | PR |
| 29 | Pre–B-ALL | 3 | BCL-2 | — | CR |
| 35 | Pre–B-ALL | 3 | BCL-2 > BCL-XL | — | NR |
| 18 | Pro–B-ALL | 2 | BCL-2 | — | CR |
| 42 | B | 3 | BCL-2 | — | PD |
| 22 | Pre–T-ALL | 2 | BCL-2 | BCL-2, BCL-XLb | SD |
| 41 | Pre–T-ALL | 3 | BCL-2 | — | NR |
| 38 | Pro–T-ALL | 3 | BCL-XL > BCL-2 >> MCL-1 | — | CR |
| 5 | T-ALL: medullary | 1 | BCL-2 | BCL-XLb | SD |
| 14 | ETP-ALL | 1 | BCL-2 | — | CR |
| 8 | ETP-ALL | 1 | BCL-2 | BCL-XLb | CR |
| 4 | ETP-ALL | 1 | BCL-2 | — | CRi |
| 15 | ETP-ALL | 1 | BCL-XL > MCL-1 | — | CR |
| 27 | ETP-ALL | 2 | BCL-XL, MCL-1, BCL-2 | — | CRi |
| 40 | ETP-ALL | 3 | BCL-2 | BCL-2, BCL-XL | SD |
| 45 | ETP-ALL | 3 | BCL-2 | — | PD |
Note: The em dash denotes patients that did not have on study samples available for BH3 profiling.
For all samples with matched BM and PB available, only 1 patient had discordant BH3 profiles between BM and PB.
On study samples collected at time of disease progression.
Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; BCL-2, B-cell lymphoma 2; BM, bone marrow; CR, complete remission; CRi, complete remission with incomplete marrow recovery; CRp, complete remission without platelet recovery; ETP-ALL, early T-cell precursor acute lymphoblastic leukemia; NR, not reached; MCL-1, myeloid cell leukemia 1; PB, peripheral blood; PD, progressive disease; PR, partial response; SD, stable disease; T-ALL, T-cell acute lymphoblastic leukemia.